ERBB2 and breast cancer: In this study, we determined that pyrotinib combined with chrysin could elicit a synergistic superiority in inhibiting HER2-positive breast cancer in vitro and in vitro than single pyrotinib or chrysin treatment via the regulation of miR-16-5p/ZBTB16/G6PD axis.